Holds one valid CEP for dabigatran etexilate mesilate, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one valid CEP for dabigatran etexilate mesilate, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds 2 valid CEPs for dabigatran etexilate mesilate, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds 2 valid CEPs for dabigatran etexilate mesilate, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one valid CEP for dabigatran etexilate mesilate, filing since 2026. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Holds one valid CEP for dabigatran etexilate mesilate, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one valid CEP for dabigatran etexilate mesilate, filing since 2026. Its GMP is recognised in 2 markets.
Holds one valid CEP for dabigatran etexilate mesilate, filing since 2025. Its GMP is recognised in 1 market.
Holds one valid CEP for dabigatran etexilate mesilate, filing since 2025. Its 2025 FDA inspection closed as OAI, and its GMP is recognised in 2 markets.
This page filters the worldwide Dabigatran Etexilate Mesilate manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free